January 12, 2020 Ruby Wallau for STAT
S AN FRANCISCO — Agios Pharmaceuticals intends to double the number of approved medicines it sells from two to four within the next six years, while also expanding into new indications and deepening its pipeline by another two programs.
The new Agios ( AGIO ) strategic plan — including a mandate to trim financial losses and become cash-flow positive — was announced Sunday ahead of a presentation by CEO Jackie Fouse on Monday morning at the J.P. Morgan Healthcare Conference. Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months! Log In | Learn More What is it? STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What's included? The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day Online intelligence briefings Frequent opportunities to engage with veteran beat reporters and industry experts Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology